1. OPUS at UTS
  2. Faculty of Business
  3. General Collection

Integrative Review of Managed Entry Agreements: Chances and Limitations.

Publisher:
Springer Science and Business Media LLC
Publication Type:
Journal Article
Citation:
PharmacoEconomics, 2020, 38, (11), pp. 1165-1185
Issue Date:
2020-07-31
Closed Access
Filename Description Size
Laba_Managed Entry Agreements.pdf931.09 kB
Adobe PDF
Copyright Clearance Process
  • Recently Added
  • In Progress
  • Closed Access
This item is closed access and not available.
Full metadata record
Abstract:
BACKGROUND AND OBJECTIVE:Managed entry agreements (MEAs) consist of a set of instruments to reduce the uncertainty and the budget impact of new high-priced medicines; however, there are concerns. There is a need to critically appraise MEAs with their planned introduction in Brazil. Accordingly, the objective of this article is to identify and appraise key attributes and concerns with MEAs among payers and their advisers, with the findings providing critical considerations for Brazil and other high- and middle-income countries. METHODS:An integrative review approach was adopted. This involved a review of MEAs across countries. The review question was 'What are the health technology MEAs that have been applied around the world?' This review was supplemented with studies not retrieved in the search known to the senior-level co-authors including key South American markets. It also involved senior-level decision makers and advisers providing guidance on the potential advantages and disadvantages of MEAs and ways forward. RESULTS:Twenty-five studies were included in the review. Most MEAs included medicines (96.8%), focused on financial arrangements (43%) and included mostly antineoplastic medicines. Most countries kept key information confidential including discounts or had not published such data. Few details were found in the literature regarding South America. Our findings and inputs resulted in both advantages including reimbursement and disadvantages including concerns with data collection for outcome-based schemes. CONCLUSIONS:We are likely to see a growth in MEAs with the continual launch of new high-priced and often complex treatments, coupled with increasing demands on resources. Whilst outcome-based MEAs could be an important tool to improve access to new innovative medicines, there are critical issues to address. Comparing knowledge, experiences, and practices across countries is crucial to guide high- and middle-income countries when designing their future MEAs.
Please use this identifier to cite or link to this item:
http://hdl.handle.net/10453/145854

Faculty of Business
General Collection